Prognostic Value of CD1B in Localised Prostate Cancer

Cheng-Hsueh Lee, Lih-Chyang Chen, Chia-Cheng Yu, Wen-Hsin Lin, Victor C. Lin, Chao-Yuan Huang, Te-Ling Lu, Shu-Pin Huang and Bo-Ying Bao
Additional contact information
Cheng-Hsueh Lee: Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
Lih-Chyang Chen: Department of Medicine, Mackay Medical College, New Taipei City 252, Taiwan
Chia-Cheng Yu: Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
Wen-Hsin Lin: Department of Pharmacy, China Medical University, Taichung 404, Taiwan
Victor C. Lin: Department of Urology, E-Da Hospital, Kaohsiung 824, Taiwan
Chao-Yuan Huang: Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan
Te-Ling Lu: Department of Pharmacy, China Medical University, Taichung 404, Taiwan
Shu-Pin Huang: Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
Bo-Ying Bao: Department of Pharmacy, China Medical University, Taichung 404, Taiwan

IJERPH, 2019, vol. 16, issue 23, 1-8

Abstract: Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09–1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.

Keywords: CD antigen; prostate cancer; biomarker; prognosis; CD1B (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/23/4723/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/23/4723/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:23:p:4723-:d:291245

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().